Synaptogenix Inc (SNPX)

[FooBarAndGrill]

-5.00 I'm dialed in. Gave "KOL" code and name, etc. Muzak.
-2:00 Welcome operator. Members of the press without MIFID (High touch access) asked to disconnect now. (Really? Sure)
-1:00 Welcome again.....
+5:00 Kory Kasimoff intro Dr Marlin Sabbagh Cleveland Clinic /// Dr. Martin Farlow Indiana University School of Medicine. Both are PI.
+10:00 Progress so far? Improved pt selection and drug targeting. Long way to go. Amyloid hypothesis? "Does not correlate well to cognition"
+16:00 Role of Amyloid? Discussion of various "MAB" trials. Removal of amyloids is associated with a stabilization of impairment.
+22:00 Interim Analysis advantage/disadvantage? Statistical penalty modest.
+26:00 Optimism? Cautious
+27:00 BAN2401 vs. Aducanumab Dosage? twice a month vs. once a month.
+29:00 Biogen Balance APOE4 carrier vs. non-carrier imbalance in placebo trial?
+31:00 Other approaches. TAU (prion-like) protein. Tangles correlate better to cognitive impairment.
+36:00 Drug Combination trials issues.
+39:00 Earlier stages disease targeting issues? Biomarkers will have good utility for screening.
+40:00 More advanced disease treatment? This was quite a long discussion by Farlow

(Farlow) Neurotrope discussion. Bryostatin-1 moderate to severe patients positive effect synaptogenesis. Benefit to patients not on Memantine. Promising drug. (Sabbagh) Agrees.

+46.00 Treatment of neuro-inflammation? Inflammation vs. amyloid approach.
+50:00 Approaches to targeting various mutations?
+51:00 other mechanisms of action?
+53:00 Email questions: Aducanumab trial? Worrisome lack of randomity.
+55:00 Getting to market? Future-cast. Expect foot dragging due to third party payment acceptance. Cost of drug due to cost of trials. More patient selection via biomarkers.
+58:00 Closing Thanks.